Investment Rating - The industry investment rating is "Positive," with expectations for overall returns exceeding the CSI 300 Index by more than 5% over the next six months [6]. Core Views - Galderma's monoclonal antibody Nemluvio has received EU approval for treating moderate to severe atopic dermatitis and prurigo nodularis, marking a significant advancement in the pharmaceutical sector [2]. - The pharmaceutical sector showed a performance increase of +0.66% on February 17, 2025, outperforming the CSI 300 Index by 0.45 percentage points, ranking 12th among 31 sub-industries [1]. - Notable stock performances included Hongbo Pharmaceutical (+20.01%), Anbiping (+20.00%), and Tianzhihang (+16.65%), while Lingrui Pharmaceutical (-4.49%), Mayinglong (-4.40%), and Kunming Pharmaceutical (-3.59%) saw declines [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on February 17, 2025, was +0.66%, outperforming the CSI 300 Index by 0.45 percentage points, with hospitals (+3.51%), medical R&D outsourcing (+3.24%), and in vitro diagnostics (+2.95%) leading the gains [1]. Company News - Wanbangde's subsidiary received FDA orphan drug designation for mecobalamin in treating ALS, which is crucial for maintaining methylation cycle balance and reducing neurotoxicity [2]. - Shanghai Laishi announced a share buyback plan of 250-500 million yuan, with a maximum price of 9.5 yuan per share, aimed at employee stock ownership plans [3]. - Hengrui Medicine's subsidiary received a notice from the National Medical Products Administration regarding the acceptance of its HR19034 eye drop application for myopia progression in children aged 6 to 12 [3].